Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's ...

Analyst Travis Steed of Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report), retaining the price ...

Medtronic, a global developer and manufacturer of medical devices for chronic diseases, is now a $111 billion (by market cap) ...

That includes the MiniMed ... performance in products from cardiac pacing therapies, cardiac surgery, defibrillation solutions, and coronary solutions. In terms of guidance, Medtronic now expects ...

Axonics (Nasdaq:AXNX) announced today that a jury unanimously ruled in its favor in a patent spat with (NYSE: MDT).

U.S. revenues grew in the mid-teens on the continued adoption of the MiniMed 780G automated insulin ... line return from the stock in the next few months. Medtronic is part of the Zacks Medical - ...

Medtronic PLC closed $2.15 below its 52-week high ($91.49), which the company reached on September 4th.

Specifically, Medtronic's diabetes and neuromodulation products may be poised for breakout ... was the firm's diabetes category, led by its MiniMed 780G automated insulin delivery (AID) system.

Medtronic sells products in many end markets in these segments ... The firm faced an FDA warning letter for Its MiniMed 600 insulin pump, which I highlighted in an earlier article.

In April, Medtronic obtained FDA approval for another new product, Inceptiv, a spinal cord stimulator for treating chronic pain. The device can automatically adjust the therapy — a unique feature — to ...

Shares of Medtronic PLC MDT advanced 1.52% to $89.47 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 ...